IL33 and colitis: Recently, IL-33 has been linked with eosinophil activation, TATE and reduced tumor growth in a model of skin cancer.13,25 By using two different CRC models, a s.c. tumor cell engraftment and an AOM+DSS-driven colitis-associated model, we can show that administration of IL-33 reduces tumor growth in CRC.